Skip to main content
Top
Published in: Clinical Rheumatology 6/2011

01-06-2011 | Original Article

Gender and age impacts on the correlations between hyperuricemia and metabolic syndrome in Chinese

Authors: Qing Zhang, Shanshan Lou, Zhaowei Meng, Xiaojun Ren

Published in: Clinical Rheumatology | Issue 6/2011

Login to get access

Abstract

Prevalence of both metabolic syndrome (MS) and hyperuricemia are increasing. However, findings regarding their relationships are inconsistent. We aimed to explore correlations between MS and hyperuricemia in a large Chinese population, emphasizing the impacts from gender and age. Data analyses were performed in 17,762 subjects randomly recruited from Tianjin municipality in China. Hyperuricemia was defined as serum uric acid (SUA) >420 μmol/L for men, >360 μmol/L for women. MS was diagnosed by the consensus criterion released in 2009 from a joint collaboration between American Heart Association and other organizations. MS was also diagnosed by Chinese Diabetes Society (CDS) criterion. Total hyperuricemic prevalence was 12.16%, with male significantly higher than female. Total MS prevalence by consensus criterion was much higher than by CDS criterion (25.56% versus 14.09%). Correlation coefficients were much greater in women than in men. SUA was significantly positively related with body mass index and waist circumference. Generally, binary logistic regression models disclosed females with high SUA were twice likely to suffer from MS than males. Young females (≤44 years old) with hyperuricemia had the highest odd ratio of 7.857 by consensus criterion; and after further adjustment by body mass index, this odd ratio was 3.040. SUA and MS were much more closely related in females than in males. Young women with hyperuricemia had the highest risk of MS.
Literature
1.
go back to reference Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef
2.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef
3.
go back to reference Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752PubMedCrossRef Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752PubMedCrossRef
4.
go back to reference Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062PubMedCrossRef Alberti KG, Zimmet P, Shaw J (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062PubMedCrossRef
5.
go back to reference Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645PubMedCrossRef Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645PubMedCrossRef
6.
go back to reference Expert Panel on Metabolic Syndrome of Chinese Diabetes Society (2004) Recommendations on metabolic syndrome of Chinese Diabetes Society (in Chinese). Chin J Diab 12:156–161 Expert Panel on Metabolic Syndrome of Chinese Diabetes Society (2004) Recommendations on metabolic syndrome of Chinese Diabetes Society (in Chinese). Chin J Diab 12:156–161
7.
go back to reference Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356–359PubMedCrossRef Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356–359PubMedCrossRef
8.
go back to reference Li ZY, Xu GB, Xia TA (2006) Prevalence rate of metabolic syndrome and dyslipidemia in a large professional population in Beijing. Atherosclerosis 184:188–192PubMedCrossRef Li ZY, Xu GB, Xia TA (2006) Prevalence rate of metabolic syndrome and dyslipidemia in a large professional population in Beijing. Atherosclerosis 184:188–192PubMedCrossRef
9.
go back to reference Li Y, Stamler J, Xiao Z et al (1997) Serum uric acid and its correlates in Chinese adult populations, urban and rural, of Beijing. The PRC–USA Collaborative Study in Cardiovascular and Cardiopulmonary Epidemiology. Int J Epidemiol 26:288–296PubMedCrossRef Li Y, Stamler J, Xiao Z et al (1997) Serum uric acid and its correlates in Chinese adult populations, urban and rural, of Beijing. The PRC–USA Collaborative Study in Cardiovascular and Cardiopulmonary Epidemiology. Int J Epidemiol 26:288–296PubMedCrossRef
10.
go back to reference Nan H, Qiao Q, Dong Y et al (2006) The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. J Rheumatol 33:1346–1350PubMed Nan H, Qiao Q, Dong Y et al (2006) The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. J Rheumatol 33:1346–1350PubMed
11.
go back to reference Sui X, Church TS, Meriwether RA et al (2008) Uric acid and the development of metabolic syndrome in women and men. Metabolism 57:845–852PubMedCrossRef Sui X, Church TS, Meriwether RA et al (2008) Uric acid and the development of metabolic syndrome in women and men. Metabolism 57:845–852PubMedCrossRef
12.
go back to reference Onat A, Uyarel H, Hergenc G et al (2006) Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 19:1055–1062PubMedCrossRef Onat A, Uyarel H, Hergenc G et al (2006) Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 19:1055–1062PubMedCrossRef
13.
go back to reference Kawamoto R, Tomita H, Oka Y et al (2006) Relationship between serum uric acid concentration, metabolic syndrome and carotid atherosclerosis. Intern Med 45:605–614PubMedCrossRef Kawamoto R, Tomita H, Oka Y et al (2006) Relationship between serum uric acid concentration, metabolic syndrome and carotid atherosclerosis. Intern Med 45:605–614PubMedCrossRef
14.
go back to reference Rho YH, Woo JH, Choi SJ et al (2008) Association between serum uric acid and the Adult Treatment Panel III-defined metabolic syndrome: results from a single hospital database. Metabolism 57:71–76PubMedCrossRef Rho YH, Woo JH, Choi SJ et al (2008) Association between serum uric acid and the Adult Treatment Panel III-defined metabolic syndrome: results from a single hospital database. Metabolism 57:71–76PubMedCrossRef
15.
go back to reference Ford ES, Li C, Cook S et al (2007) Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 115:2526–2532PubMedCrossRef Ford ES, Li C, Cook S et al (2007) Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 115:2526–2532PubMedCrossRef
16.
go back to reference Niskanen LK, Laaksonen DE, Nyyssonen K et al (2004) Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 164:1546–1551PubMedCrossRef Niskanen LK, Laaksonen DE, Nyyssonen K et al (2004) Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 164:1546–1551PubMedCrossRef
17.
go back to reference Ioachimescu AG, Brennan DM, Hoar BM et al (2007) Serum uric acid, mortality and glucose control in patients with type 2 diabetes mellitus: a PreCIS database study. Diabet Med 24:1369–1374PubMedCrossRef Ioachimescu AG, Brennan DM, Hoar BM et al (2007) Serum uric acid, mortality and glucose control in patients with type 2 diabetes mellitus: a PreCIS database study. Diabet Med 24:1369–1374PubMedCrossRef
18.
go back to reference Choi HK, Ford ES (2007) Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120:442–447PubMedCrossRef Choi HK, Ford ES (2007) Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 120:442–447PubMedCrossRef
19.
go back to reference Culleton BF, Larson MG, Kannel WB et al (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131:7–13PubMed Culleton BF, Larson MG, Kannel WB et al (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131:7–13PubMed
20.
go back to reference Sakata K, Hashimoto T, Ueshima H et al (2001) Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980–1994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged. Eur J Epidemiol 17:461–468PubMedCrossRef Sakata K, Hashimoto T, Ueshima H et al (2001) Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980–1994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged. Eur J Epidemiol 17:461–468PubMedCrossRef
21.
go back to reference Portney L, Watkins M (2000) Foundations of clinical research: applications to practice. Upper Saddle River, Prentice Hall, pp 79–110 Portney L, Watkins M (2000) Foundations of clinical research: applications to practice. Upper Saddle River, Prentice Hall, pp 79–110
22.
23.
go back to reference Mikkelsen WM, Dodge HJ, Valkenburg H (1965) The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia: Tecumseh, Michigan 1959–1960. Am J Med 39:242–251PubMedCrossRef Mikkelsen WM, Dodge HJ, Valkenburg H (1965) The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia: Tecumseh, Michigan 1959–1960. Am J Med 39:242–251PubMedCrossRef
24.
go back to reference Sumino H, Ichikawa S, Kanda T et al (1999) Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. Lancet 354:650PubMed Sumino H, Ichikawa S, Kanda T et al (1999) Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. Lancet 354:650PubMed
25.
go back to reference Hak AE, Choi HK (2008) Menopause, postmenopausal hormone use and serum uric acid levels in US women—the Third National Health and Nutrition Examination Survey. Arthritis Res Ther 10:R116PubMedCrossRef Hak AE, Choi HK (2008) Menopause, postmenopausal hormone use and serum uric acid levels in US women—the Third National Health and Nutrition Examination Survey. Arthritis Res Ther 10:R116PubMedCrossRef
26.
go back to reference Anton FM, Garcia Puig J, Ramos T et al (1986) Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism 35:343–348PubMedCrossRef Anton FM, Garcia Puig J, Ramos T et al (1986) Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism 35:343–348PubMedCrossRef
27.
go back to reference Yahyaoui R, Esteva I, Haro-Mora JJ et al (2008) Effect of long-term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons. J Clin Endocrinol Metab 93:2230–2233PubMedCrossRef Yahyaoui R, Esteva I, Haro-Mora JJ et al (2008) Effect of long-term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons. J Clin Endocrinol Metab 93:2230–2233PubMedCrossRef
28.
go back to reference Carr MC (2003) The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88:2404–2411PubMedCrossRef Carr MC (2003) The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88:2404–2411PubMedCrossRef
29.
go back to reference Starcke S, Vollmer G (2006) Is there an estrogenic component in the metabolic syndrome? Genes Nutr 1:177–188PubMedCrossRef Starcke S, Vollmer G (2006) Is there an estrogenic component in the metabolic syndrome? Genes Nutr 1:177–188PubMedCrossRef
30.
go back to reference Park YW, Zhu S, Palaniappan L et al (2003) The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 163:427–436PubMedCrossRef Park YW, Zhu S, Palaniappan L et al (2003) The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 163:427–436PubMedCrossRef
31.
go back to reference Sowers M, Zheng H, Tomey K et al (2007) Changes in body composition in women over 6 years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 92:895–901PubMedCrossRef Sowers M, Zheng H, Tomey K et al (2007) Changes in body composition in women over 6 years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 92:895–901PubMedCrossRef
32.
go back to reference Torrens JI, Sutton-Tyrrell K, Zhao X et al (2009) Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women’s Health Across the Nation. Menopause 16:257–264PubMedCrossRef Torrens JI, Sutton-Tyrrell K, Zhao X et al (2009) Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women’s Health Across the Nation. Menopause 16:257–264PubMedCrossRef
33.
go back to reference Janssen I, Powell LH, Crawford S et al (2008) Menopause and the metabolic syndrome: the Study of Women’s Health Across the Nation. Arch Intern Med 168:1568–1575PubMedCrossRef Janssen I, Powell LH, Crawford S et al (2008) Menopause and the metabolic syndrome: the Study of Women’s Health Across the Nation. Arch Intern Med 168:1568–1575PubMedCrossRef
34.
go back to reference Facchini F, Chen YD, Hollenbeck CB et al (1991) Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266:3008–3011PubMedCrossRef Facchini F, Chen YD, Hollenbeck CB et al (1991) Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266:3008–3011PubMedCrossRef
35.
go back to reference Tsunoda S, Kamide K, Minami J et al (2002) Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. Am J Hypertens 15:697–701PubMedCrossRef Tsunoda S, Kamide K, Minami J et al (2002) Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. Am J Hypertens 15:697–701PubMedCrossRef
36.
go back to reference Nakanishi N, Suzuki K, Kawashimo H et al (1999) Serum uric acid: correlation with biological, clinical and behavioral factors in Japanese men. J Epidemiol 9:99–106PubMed Nakanishi N, Suzuki K, Kawashimo H et al (1999) Serum uric acid: correlation with biological, clinical and behavioral factors in Japanese men. J Epidemiol 9:99–106PubMed
37.
go back to reference Poehlman ET, Toth MJ, Ades PA et al (1997) Menopause-associated changes in plasma lipids, insulin-like growth factor I and blood pressure: a longitudinal study. Eur J Clin Invest 27:322–326PubMedCrossRef Poehlman ET, Toth MJ, Ades PA et al (1997) Menopause-associated changes in plasma lipids, insulin-like growth factor I and blood pressure: a longitudinal study. Eur J Clin Invest 27:322–326PubMedCrossRef
38.
go back to reference Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213–219PubMedCrossRef Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213–219PubMedCrossRef
39.
go back to reference Clark JM, Brancati FL, Diehl AM (2003) The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98:960–967PubMedCrossRef Clark JM, Brancati FL, Diehl AM (2003) The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98:960–967PubMedCrossRef
41.
go back to reference Marchesini G, Brizi M, Bianchi G et al (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844–1850PubMedCrossRef Marchesini G, Brizi M, Bianchi G et al (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844–1850PubMedCrossRef
42.
go back to reference Mellen PB, Bleyer AJ, Erlinger TP et al (2006) Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 48:1037–1042PubMedCrossRef Mellen PB, Bleyer AJ, Erlinger TP et al (2006) Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 48:1037–1042PubMedCrossRef
43.
go back to reference Liang J, Xue Y, Zou C et al (2009) Serum uric acid and prehypertension among Chinese adults. J Hypertens 27:1761–1765PubMedCrossRef Liang J, Xue Y, Zou C et al (2009) Serum uric acid and prehypertension among Chinese adults. J Hypertens 27:1761–1765PubMedCrossRef
44.
go back to reference Khosla UM, Zharikov S, Finch JL et al (2005) Hyperuricemia induces endothelial dysfunction. Kidney Int 67:1739–1742PubMedCrossRef Khosla UM, Zharikov S, Finch JL et al (2005) Hyperuricemia induces endothelial dysfunction. Kidney Int 67:1739–1742PubMedCrossRef
Metadata
Title
Gender and age impacts on the correlations between hyperuricemia and metabolic syndrome in Chinese
Authors
Qing Zhang
Shanshan Lou
Zhaowei Meng
Xiaojun Ren
Publication date
01-06-2011
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 6/2011
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-010-1660-7

Other articles of this Issue 6/2011

Clinical Rheumatology 6/2011 Go to the issue

Letter to the Editor

Response to Licciardone

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.